As in every joint reimbursement process, the involved countries Belgium and the Netherlands, assessed the eligibility of Hemgenix® for joint negotiations after the recently finalised joint Health Technology Assessment process. Hemgenix® is a one-shot therapy for the treatment of...
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Belgium and the Netherlands opt for individual negotiations after a joint assessment of gene therapy Hemgenix®
Belgium and the Netherlands complete joint HTA report on gene therapy Hemgenix®
Hemgenix® is a gene therapy product for the treatment of adults with severe and moderately severe haemophilia B, who have not developed inhibitors against factor IX. Cross-border consultations resulted in a scientific and budget impact analysis report, approved in both countries...
Steering Committee Meeting of the Beneluxa initiative
On June 25, 2024, the Steering Committee of the Beneluxa Initiative met in Brussels, Belgium. Key topics of discussion included: Insights in national policies and politics Updates from the Domain Task Forces (DTFs) including the DTFs pricing and reimbursement, HTA and information...